These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 9508511)
1. Effect of potent urease inhibitor, fluorofamide, on Helicobacter sp. in vivo and in vitro. Pope AJ; Toseland CD; Rushant B; Richardson S; McVey M; Hills J Dig Dis Sci; 1998 Jan; 43(1):109-19. PubMed ID: 9508511 [TBL] [Abstract][Full Text] [Related]
2. Urea, fluorofamide, and omeprazole treatments alter helicobacter colonization in the mouse gastric mucosa. Aristoteli LP; O'Rourke JL; Danon S; Larsson H; Mellgard B; Mitchell H; Lee A Helicobacter; 2006 Oct; 11(5):460-8. PubMed ID: 16961809 [TBL] [Abstract][Full Text] [Related]
3. Development of a 14C-urea breath test in ferrets colonised with Helicobacter mustelae: effects of treatment with bismuth, antibiotics, and urease inhibitors. McColm AA; Bagshaw JA; O'Malley CF Gut; 1993 Feb; 34(2):181-6. PubMed ID: 8432469 [TBL] [Abstract][Full Text] [Related]
4. Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant. Sjöström JE; Larsson H J Med Microbiol; 1996 Jun; 44(6):425-33. PubMed ID: 8636959 [TBL] [Abstract][Full Text] [Related]
5. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829 [TBL] [Abstract][Full Text] [Related]
6. Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. Vakil N; Cutler A Am J Gastroenterol; 1999 May; 94(5):1197-9. PubMed ID: 10235192 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection. Zheng Q; Pan Y; Zhang L; Xiao SD Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231 [TBL] [Abstract][Full Text] [Related]
8. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS; Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562 [TBL] [Abstract][Full Text] [Related]
9. High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates. Sánchez-Delgado J; García-Iglesias P; Castro-Fernández M; Bory F; Barenys M; Bujanda L; Lisozain J; Calvo MM; Torra S; Gisbert JP; Calvet X Aliment Pharmacol Ther; 2012 Jul; 36(2):190-6. PubMed ID: 22591220 [TBL] [Abstract][Full Text] [Related]
10. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin. Sontag SJ; O'Connell S; Schnell T; Chejfec G; Seidel J; Sonnenberg A Am J Gastroenterol; 2001 May; 96(5):1390-5. PubMed ID: 11374672 [TBL] [Abstract][Full Text] [Related]
11. The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication. Avidan B; Melzer E; Keller N; Bar-Meir S Isr Med Assoc J; 2001 Mar; 3(3):163-5. PubMed ID: 11303370 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. Park KN; Hahm JS; Kim HJ Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924 [TBL] [Abstract][Full Text] [Related]
13. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial. Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100 [TBL] [Abstract][Full Text] [Related]
14. Seven-Day Bismuth-based Quadruple Therapy as an Initial Treatment for Helicobacter pylori Infection in a High Metronidazole Resistant Area. Vilaichone RK; Prapitpaiboon H; Gamnarai P; Namtanee J; Wongcha-um A; Chaithongrat S; Mahachai V Asian Pac J Cancer Prev; 2015; 16(14):6089-92. PubMed ID: 26320500 [TBL] [Abstract][Full Text] [Related]
16. [Effectiveness of triple therapy to eradicate H. pylori in patients after failed therapy with omeprazole/amoxicillin]. Zala G; Schwery S; Giezendanner S; Flury R; Wüst J; Meyenberger C; Wirth HP Schweiz Med Wochenschr; 1996 Feb; 126(5):153-8. PubMed ID: 8685685 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of ranitidine bismuth citrate plus amoxycillin and clarithromycin as first- or second-line therapy to cure Helicobacter pylori infection. Tursi A; Brandimarte G; Giorgetti G; Modeo ME; Gigliobianco A Hepatogastroenterology; 2002; 49(46):1006-9. PubMed ID: 12143188 [TBL] [Abstract][Full Text] [Related]
18. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics. Marcus EA; Sachs G; Scott DR Aliment Pharmacol Ther; 2015 Oct; 42(7):922-33. PubMed ID: 26238858 [TBL] [Abstract][Full Text] [Related]
19. [Detection of Helicobacter pylori and antimicrobial resistance in gastric biopsy specimens]. Cağdaş U; Otağ F; Tezcan S; Sezgin O; Aslan G; Emekdaş G Mikrobiyol Bul; 2012 Jul; 46(3):398-409. PubMed ID: 22951652 [TBL] [Abstract][Full Text] [Related]
20. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Bell GD; Powell KU; Burridge SM; Bowden AN; Rameh B; Bolton G; Purser K; Harrison G; Brown C; Gant PW Q J Med; 1993 Nov; 86(11):743-50. PubMed ID: 8265776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]